UNITED KINGDOM – Dunad Therapeutics, a biopharmaceutical company focused on developing next-generation targeted protein degradation therapies, has announced a strategic collaboration and license agreement with Novartis to develop orally bioavailable…
Read MoreDunad Therapeutics, Novartis in strategic deal to develop novel Targeted Protein degrader
